Generate a tailored SOP for Dr. Scott Walsh. Improve your application with a focused, well-structured draft.
Scott Walsh is an adjunct faculty member at the Ontario Veterinary College (OVC) at the University of Guelph, focusing on the immunomodulatory properties of oncolytic viruses and their impact on cancer immunotherapies. His research explores how these viruses selectively replicate in tumor cells and their ability to stimulate tumor-specific T cells. By understanding the inflammatory profiles of different oncolytic viruses, such as the vesicular stomatitis virus (VSV) and the vaccinia virus (VacV), Walsh aims to enhance the efficacy of cancer vaccines while mitigating autoimmune toxicity. His findings suggest that while VSV can provoke significant inflammation beneficial for cancer therapy, it may also lead to harmful autoimmune effects, particularly when high levels of T1IFN are produced. By blocking T1IFN signaling, Walsh has demonstrated a potential method to reduce these harmful effects while maintaining therapeutic benefits. Overall, his work bridges the gap between viral immunotherapy and clinical application, offering insights into improving cancer immunotherapy outcomes for patients.
University of Guelph • Guelph, ON
Department of Clinical Studies. Offers MSc by thesis (2 years) and MSc by coursework (1 year).